AbbVie Inc. (TSX:ABBV)
Canada · Delayed Price · Currency is CAD 40.81
+0.57 (1.42%)
Oct 30, 2026, 3:50 PM EDT
AbbVie Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 66,014 | 61,160 | 56,334 | 54,318 | 58,054 | 56,197 | |
Revenue Growth | 10.68% | 8.57% | 3.71% | -6.44% | 3.30% | 22.69% |
Cost of Revenue | 17,349 | 17,357 | 16,689 | 16,826 | 16,527 | 17,314 |
Gross Profit | 48,665 | 43,803 | 39,645 | 37,492 | 41,527 | 38,883 |
Selling, General & Admin | 14,740 | 13,644 | 14,099 | 12,419 | 14,584 | 11,872 |
Research & Development | 9,871 | 9,068 | 8,131 | 7,038 | 6,487 | 6,820 |
Other Operating Expenses | -18 | -24 | -7 | -179 | 228 | 432 |
Operating Expenses | 24,593 | 22,688 | 22,223 | 19,278 | 21,299 | 19,124 |
Operating Income | 24,072 | 21,115 | 17,422 | 18,214 | 20,228 | 19,759 |
Interest Expense | -2,933 | -2,893 | -2,808 | -2,224 | -2,230 | -2,423 |
Interest & Investment Income | 266 | 266 | 648 | 540 | 186 | 39 |
Currency Exchange Gain (Loss) | -58 | -58 | -21 | -146 | -148 | -51 |
Other Non Operating Income (Expenses) | 159 | 403 | 271 | 190 | 142 | 55 |
EBT Excluding Unusual Items | 21,506 | 18,833 | 15,512 | 16,574 | 18,178 | 17,379 |
Merger & Restructuring Charges | -253 | -95 | -792 | -288 | -539 | -587 |
Gain (Loss) on Sale of Assets | - | - | - | - | 172 | - |
Asset Writedown | - | -847 | -4,476 | -4,130 | -876 | - |
Other Unusual Items | -5,923 | -6,278 | -3,771 | -5,128 | -2,761 | -2,679 |
Pretax Income | 12,814 | 6,597 | 3,716 | 6,250 | 13,477 | 12,989 |
Income Tax Expense | 2,466 | 2,364 | -570 | 1,377 | 1,632 | 1,440 |
Earnings From Continuing Operations | 10,348 | 4,233 | 4,286 | 4,873 | 11,845 | 11,549 |
Minority Interest in Earnings | -6 | -7 | -8 | -10 | -9 | -7 |
Net Income | 10,342 | 4,226 | 4,278 | 4,863 | 11,836 | 11,542 |
Preferred Dividends & Other Adjustments | 40 | 40 | 40 | 43 | 54 | 74 |
Net Income to Common | 10,302 | 4,186 | 4,238 | 4,820 | 11,782 | 11,468 |
Net Income Growth | 338.76% | -1.23% | -12.07% | -59.09% | 2.74% | 151.71% |
Shares Outstanding (Basic) | 1,769 | 1,769 | 1,769 | 1,768 | 1,771 | 1,770 |
Shares Outstanding (Diluted) | 1,773 | 1,773 | 1,773 | 1,773 | 1,778 | 1,777 |
Shares Change | - | - | - | -0.28% | 0.06% | 6.22% |
EPS (Basic) | 5.82 | 2.37 | 2.40 | 2.73 | 6.65 | 6.48 |
EPS (Diluted) | 5.81 | 2.36 | 2.39 | 2.72 | 6.63 | 6.45 |
EPS Growth | 339.80% | -1.26% | -12.13% | -58.97% | 2.79% | 137.13% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | 17,816 | 17,832 | 22,062 | 24,248 | 21,990 |
Free Cash Flow Per Share | - | 10.05 | 10.06 | 12.44 | 13.64 | 12.38 |
Dividend Per Share | 6.920 | 6.650 | 6.290 | 5.990 | 5.710 | 5.310 |
Dividend Growth | 5.49% | 5.72% | 5.01% | 4.90% | 7.53% | 9.71% |
Gross Margin | 73.72% | 71.62% | 70.38% | 69.02% | 71.53% | 69.19% |
Operating Margin | 36.46% | 34.52% | 30.93% | 33.53% | 34.84% | 35.16% |
Profit Margin | 15.61% | 6.84% | 7.52% | 8.87% | 20.29% | 20.41% |
Free Cash Flow Margin | - | 29.13% | 31.65% | 40.62% | 41.77% | 39.13% |
EBITDA | 31,708 | 29,254 | 25,808 | 26,912 | 28,695 | 28,280 |
EBITDA Margin | 48.03% | 47.83% | 45.81% | 49.55% | 49.43% | 50.32% |
D&A For EBITDA | 7,636 | 8,139 | 8,386 | 8,698 | 8,467 | 8,521 |
EBIT | 24,072 | 21,115 | 17,422 | 18,214 | 20,228 | 19,759 |
EBIT Margin | 36.46% | 34.52% | 30.93% | 33.53% | 34.84% | 35.16% |
Effective Tax Rate | 19.24% | 35.83% | - | 22.03% | 12.11% | 11.09% |
Advertising Expenses | - | 2,100 | 2,100 | 2,200 | 2,000 | 2,100 |